Skip to main content
Top
Published in: Annals of Surgical Oncology 7/2018

01-07-2018 | Breast Oncology

Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer

Authors: Armando E. Giuliano, MD, Stephen B. Edge, MD, Gabriel N. Hortobagyi, MD

Published in: Annals of Surgical Oncology | Issue 7/2018

Login to get access

Excerpt

Since its inception in 1977, the American Joint Committee on Cancer (AJCC) has published a staging system based on anatomic findings: tumor size (T), nodal status (N), and metastases (M). This staging system has evolved, not only encompassing a wide spectrum of tumors but also including multiple updates that enable physicians to utilize new information and outcomes for management strategies in different malignancies. The breast cancer staging system has always been based similarly on TNM classification despite the fact that, for several years, clinicians in practice have used a number of biologic factors to describe the patient’s disease, outcomes, and appropriate therapy. …
Literature
1.
go back to reference Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.CrossRefPubMed Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.CrossRefPubMed
3.
go back to reference Wolff AC, Hammond ME, Hicks DG, et al., American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013. https://doi.org/10.1200/jco.2013.50.9984.CrossRefPubMed Wolff AC, Hammond ME, Hicks DG, et al., American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013. https://​doi.​org/​10.​1200/​jco.​2013.​50.​9984.CrossRefPubMed
5.
go back to reference Nitz U, Gluz O, Christgen M, et al. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res Treat. 2017;165(3):573–83. https://doi.org/10.1007/s10549-017-4358-6.CrossRefPubMed Nitz U, Gluz O, Christgen M, et al. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res Treat. 2017;165(3):573–83. https://​doi.​org/​10.​1007/​s10549-017-4358-6.CrossRefPubMed
Metadata
Title
Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer
Authors
Armando E. Giuliano, MD
Stephen B. Edge, MD
Gabriel N. Hortobagyi, MD
Publication date
01-07-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 7/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6486-6

Other articles of this Issue 7/2018

Annals of Surgical Oncology 7/2018 Go to the issue